MedPath

Oral Care With Propolis in Pediatric Oncology Patients

Not Applicable
Completed
Conditions
Oral Mucositis
Interventions
Biological: Placebo
Biological: propolis
Registration Number
NCT05400031
Lead Sponsor
Izmir Katip Celebi University
Brief Summary

According to the data from the World Health Organization, approximately 14 million people are diagnosed with cancer every year, and this number is expected to increase further in the next 10 years. Multidisciplinary treatment consisting of chemotherapy, radiotherapy and surgery is applied in childhood cancers. In chemotherapy, the target is cancerous cells, but high doses of chemotherapeutic agents do not have selectivity. Intact tissue cells are also affected by this cytotoxicity. Mucositis develops in the patient, especially as a result of the mucosal cells being affected. Mucositis is defined as damage to the mucosa lining the oral cavity, pharynx, larynx, oesophagus and gastrointestinal tract due to cancer treatment. It is one of the most important side effects of both chemotherapy and radiotherapy. This study is carried out to determine the effectiveness of propolis in preventing the formation of oral mucositis due to multiple use of chemotherapeutic drugs.

Detailed Description

According to the data from the World Health Organization, approximately 14 million people are diagnosed with cancer every year, and this number is expected to increase further in the next 10 years. Multidisciplinary treatment consisting of chemotherapy, radiotherapy and surgery is applied in childhood cancers. In chemotherapy, the target is cancerous cells, but high doses of chemotherapeutic agents do not have selectivity. Intact tissue cells are also affected by this cytotoxicity. Mucositis develops in the patient, especially as a result of the mucosal cells being affected. Mucositis is defined as damage to the mucosa lining the oral cavity, pharynx, larynx, oesophagus and gastrointestinal tract due to cancer treatment. It is one of the most important side effects of both chemotherapy and radiotherapy. This study is carried out to determine the effectiveness of propolis in preventing the formation of oral mucositis due to multiple uses of chemotherapeutic drugs.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
108
Inclusion Criteria
  • Volunteering to participate in the study
  • Receiving chemotherapy treatment for lymphoproliferative malignant disease (leukaemia, lymphoma) or other childhood solid tumour (such as central nervous system tumour, neuroblastoma, osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, hepatoblastoma, germ cell tumours)
  • Being between the ages of 2-18 (Although there is no harm in using propolis, it is inconvenient for children under the age of 2 to use honey and its by-products due to botulism)
  • No development of oral mucositis
  • The child who does not smoke
Exclusion Criteria
  • The patient does not receive head and neck RT (increases the incidence of oral mucositis by 40%).
  • The patient is allergic to bee products.
  • Exclusion Criteria and Practices in this Case:
  • Development of an allergic reaction to propolis (Applied oral care protocol is stopped, removed from the sample)
  • Starting RT
  • The child's need for MV support

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
placebo groupPlaceboIn this group, the researcher will provide the participants with a propolis vehicle
propolis grouppropolisIn this group, the researcher will provide the participants with a propolis solution.
Primary Outcome Measures
NameTimeMethod
Oral mucositis gradingtenth day of the intervention

Oral Mucositis Assessment Scale is a classification method accepted by the World Health Organization and used all over the world. It has standard clauses that will be interpreted in the same way by all people. However, in order to ignore the differences in interpretation, multi-research evaluation will be used in the first 20 observations and the consistency between the observers will be analyzed with Kappa analysis and the follow-ups will continue.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Tepecik Research and Training Hospital

🇹🇷

İzmir, Turkey

© Copyright 2025. All Rights Reserved by MedPath